Funding Details
- Awarder
- Inbox
- Date Award
- March 17, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Traction
- Latigo's lead candidate LTG-001 is in a Phase 2 clinical trial for acute pain relief, with results expected later this year. The company has raised a total of $285 million across its Series A and B funding rounds.
- Company Description
- Latigo Biotherapeutics is a private drug company developing experimental non-opioid pain medicines targeting the NaV1.8 ion channel in peripheral nerve cells. The company aims to provide pain relief without the addictive risks associated with opioids.
- Market
- Pain Management
- Location
-
USA
- Coinvestors
- Blue Owl Capital, 5AM Ventures, Foresite Capital, Alexandria Venture Investments, Westlake Village BioPartners
Links